Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 6/20 | 0.58 |
| ▸ | MMP3 | P08254 | 13/20 | 0.46 |
| ▸ | MMP2 | P08253 | 12/20 | 0.42 |
| ▸ | MMP1 | P03956 | 11/20 | 0.42 |
| ▸ | MMP7 | P09237 | 9/20 | 0.42 |
| ▸ | MMP9 | P14780 | 2/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6293008 | 0.90 | BIRC2 (0.44) | BIRC2MMP3MMP9 | |
| SCHEMBL14279424 | 0.88 | BIRC2 (0.55) | BIRC2MMP3MMP2MMP1MMP7 | |
| SCHEMBL6292975 | 0.88 | BIRC2 (0.45) | BIRC2MMP3MMP2MMP1MMP7 | |
| SCHEMBL6294138 | 0.87 | BIRC2 (0.58) | BIRC2MMP3MMP2MMP1MMP7 | |
| Actinonin SCHEMBL14490676 | 0.87 | BIRC2 (0.56) | BIRC2MMP3MMP2MMP1MMP7 | |
| Actinonin SCHEMBL123273 | 0.87 | BIRC2 (0.56) | BIRC2MMP3MMP2MMP1MMP7 | |
| Actinonin SCHEMBL279122 | 0.87 | BIRC2 (0.56) | BIRC2MMP3MMP2MMP1MMP7 | |
| Actinonin SCHEMBL12601775 | 0.87 | BIRC2 (0.56) | BIRC2MMP3MMP2MMP1MMP7 | |
| Actinonin SCHEMBL279450 | 0.87 | BIRC2 (0.56) | BIRC2MMP3MMP2MMP1MMP7 | |
| SCHEMBL18328823 | 0.85 | MMP3 (0.49) | BIRC2MMP3MMP2MMP1MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272667-A1 | Analogs and derivatives of (S,S,R)-(-)-actinonin and uses therefor | SCHEINBERG DAVID | 2005-12-08 | — | — | US | claimed |
| US-20040019083-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-01-29 | — | — | US | claimed |
| US-6660741-B2 | Coupling an O-protected methoxypyrrolidine or derivatives with N-protected amino acid 2,5-dioxo-pyrrolidinyl ester to form intermediate, deportecting with trifluoroacetic acid to form pyrrolidine-1-carbonyl-2-methylamine or derivatives | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-12-09 | — | — | US | claimed |
| US-20020198156-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2002-12-26 | — | — | US | claimed |
| US-20050272667-A1 | Analogs and derivatives of (S,S,R)-(-)-actinonin and uses therefor | SCHEINBERG DAVID | 2005-12-08 | — | — | US | disclosed |
| US-6887887-B2 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2005-05-03 | — | — | US | disclosed |
| US-20040019083-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-01-29 | — | — | US | disclosed |
| US-6660741-B2 | Coupling an O-protected methoxypyrrolidine or derivatives with N-protected amino acid 2,5-dioxo-pyrrolidinyl ester to form intermediate, deportecting with trifluoroacetic acid to form pyrrolidine-1-carbonyl-2-methylamine or derivatives | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-12-09 | — | — | US | disclosed |
| US-20020198156-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198156-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | HASPIN, CYTH2, ACTR3 | BIRC2 675/4885MMP3 2111/4885MMP2 2210/4885 |
| US-20040019083-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | HASPIN, CYTH2, CYTH3 | BIRC2 696/4885MMP3 2147/4885MMP2 2144/4885 |
| US-20050272667-A1 | Analogs and derivatives of (S,S,R)-(-)-actinonin and uses therefor | CYTH3, ACTR3, HASPIN | BIRC2 813/4885MMP3 1631/4885MMP2 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.